Johnson & Johnson (JNJ) Reports Q4 Results, Ticks Lower as FY Guidance Falls Short
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $270.24 +1.07%
Financial Fact:
Interest income: -97M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Interest income: -97M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
This morning shares of blue-chip Johnson & Johnson (NYSE: JNJ) ticked lower after it reported Q4 results. While earnings topped estimates, full year guidance came in below expectations, resulting in early selling pressure.
Q4 revenue for the quarter came in at $17.6 billion versus the consensus estimate of $17.67 billion.
The company reported worldwide Consumer sales of $14.4 billion for the full-year 2012 represented a decrease of 2.9 percent versus the prior year. Worldwide Pharmaceutical sales of $25.4 billion for the full-year 2012 represented an increase of 4.0 percent. Worldwide Medical Devices and Diagnostics sales came in at $27.4 billion for the full-year 2012 represented an increase of 6.4 percent versus the prior year.
On the bottom line, Johnson & Johnson reported non-GAAP Q4 EPS of $1.19, $0.02 better than the analyst estimate of $1.17.
Analyst at Goldman Sachs note a lower tax rate of 18%, versus their estimate of 21%, contibuted 5 cents to EPS.
Looking forward, Johnson & Johnson sees FY2013 EPS of $5.35-.5.45, 9 cents shy of Street estimates of $5.49.
Leerink Swan analysts called it a "low quality EPS beat." They said the lower-than-expected 2013 guidance and $100 million MD&D miss could pressure the stock and potentially the MedTech group broadly.
Aside from earnings, Johnson & Johnson said it is exploring strategic options for its Ortho Clinical Diagnostics (OCD) business. Options include a possible divestiture if it is determined that OCD could have greater potential as part of another organization whose focus is more closely aligned with its core strengths, or by operating as a stand-alone company.
Shares of JNJ last traded at $72.82, down 0.55%.
Q4 revenue for the quarter came in at $17.6 billion versus the consensus estimate of $17.67 billion.
The company reported worldwide Consumer sales of $14.4 billion for the full-year 2012 represented a decrease of 2.9 percent versus the prior year. Worldwide Pharmaceutical sales of $25.4 billion for the full-year 2012 represented an increase of 4.0 percent. Worldwide Medical Devices and Diagnostics sales came in at $27.4 billion for the full-year 2012 represented an increase of 6.4 percent versus the prior year.
On the bottom line, Johnson & Johnson reported non-GAAP Q4 EPS of $1.19, $0.02 better than the analyst estimate of $1.17.
Analyst at Goldman Sachs note a lower tax rate of 18%, versus their estimate of 21%, contibuted 5 cents to EPS.
Looking forward, Johnson & Johnson sees FY2013 EPS of $5.35-.5.45, 9 cents shy of Street estimates of $5.49.
Leerink Swan analysts called it a "low quality EPS beat." They said the lower-than-expected 2013 guidance and $100 million MD&D miss could pressure the stock and potentially the MedTech group broadly.
Aside from earnings, Johnson & Johnson said it is exploring strategic options for its Ortho Clinical Diagnostics (OCD) business. Options include a possible divestiture if it is determined that OCD could have greater potential as part of another organization whose focus is more closely aligned with its core strengths, or by operating as a stand-alone company.
Shares of JNJ last traded at $72.82, down 0.55%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BofA says momentum style supported by earnings revisions
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
